Coronary Artery Disease
Conditions
Keywords
coronary artery disease, percutaneous coronary intervention, atorvastatin
Brief summary
This study investigates potential protective effect of atorvastatin pre-treatment in patient with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). Patient are randomized to two groups: atorvastatin pre-treatment group (80mg atorvastatin two days before PCI) and control group (PCI without atorvastatin pretreatment). Endpoint is myocardial infarction measured by troponin I and creatine kinase myocardial band.
Detailed description
Randomized studies have shown that pre-treatment with atorvastatin may reduced periprocedural myocardial in patient with stable angina during elective PCI. These data provide evidence-based support for using atorvastatin 7 days before PCI (dosage 40mg/d), alternatively three or more days (unknown dosage). We want to confirm this results for shorter pre-treatment period (two days) with dosage 80mg per day.
Interventions
DRUGAtorvastatin
two days 80mg atorvastatin pre-treatment before PCI
Sponsors
University Hospital, Motol
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* stable angina in last month * indication for percutaneous coronary intervention * informed consent
Exclusion criteria
* acute coronary syndrome in last 14 days * renal insufficiency (creatinine more 150 µmol/l) * diseases severely limiting prognosis * immunosuppressive treatment * statin one month before randomization * occlusion of the coronary artery * previous participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| periprocedural myocardial infarction measured by troponin I level | 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| periprocedural myocardial infarction measured by creatine kinase myocardial band | 24 hours |
Countries
Czechia
Outcome results
None listed